ACTH as a treatment for acute crystal-induced arthritis: Update on clinical evidence and mechanisms of action

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 5, 2014, Pages 648-653

  Daoussis, Dimitrios ^a   Antonopoulos, Ioannis ^a   Andonopoulos, Andrew P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

ACTH; Crystal induced arthritis; Gout; Pseudogout; Treatment

Indexed keywords

CALCIUM PYROPHOSPHATE; COLCHICINE; CORTICOTROPIN; INDOMETACIN; MELANOCORTIN RECEPTOR; STEROID; TRIAMCINOLONE;

ABDOMINAL DISCOMFORT; ACUTE CRYSTAL INDUCED ARTHRITIS; ADRENAL GLAND; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; GOUT; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LOW DRUG DOSE; PRIORITY JOURNAL; PSEUDOGOUT; RETROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; STEROID RELEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ARTHRITIS, GOUTY; CHONDROCALCINOSIS;

ADRENOCORTICOTROPIC HORMONE; ARTHRITIS, GOUTY; CHONDROCALCINOSIS; GOUT; HUMANS; TREATMENT OUTCOME;

EID: 84898834494     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.09.006     Document Type: Review

References (28)

1. Neogi T. Clinical practice. Gout. N Engl J Med 2011, 364:443-452.
2. Keenan R.T., O'Brien W.R., Lee K.H., Crittenden D.B., Fisher M.C., Goldfarb D.S., et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011, 124:155-163.
3. Ghosh P., Cho M., Rawat G., Simkin P.A., Gardner G.C. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013, 65:1381-1384.
4. McGonagle D., Tan A.L., Madden J., Emery P., McDermott M.F. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008, 58:631-633.
5. Gutman A.B., Yu T.F. Effects of adrenocorticotropic hormone (ACTH) in gout. Am J Med 1950, 9:24-30.
6. Ritter J., Kerr L.D., Valeriano-Marcet J., Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994, 21:696-699.
7. Axelrod D., Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988, 31:803-805.
8. Siegel L.B., Alloway J.A., Nashel D.J. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994, 21:1325-1327.
9. Daoussis D., Antonopoulos I., Yiannopoulos G., Andonopoulos A.P. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine 2013, 80:291-294.
10. Getting S.J., Kaneva M., Bhadresa Y., Renshaw D., Leoni G., Patel H.B., et al. Melanocortin peptide therapy for the treatment of arthritic pathologies. ScientificWorldJournal 2009, 9:1394-1414.
11. Brzoska T., Luger T.A., Maaser C., Abels C., Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008, 29:581-602.
12. Getting S.J., Christian H.C., Flower R.J., Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002, 46:2765-2775.
13. Zhang W., Doherty M., Pascual E., Barskova V., Guerne P.A., Jansen T.L., et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011, 70:571-575.
14. Daoussis D., Antonopoulos I., Yiannopoulos G., Andonopoulos A.P. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine 2013, [Epub ahead of print].
15. Montero-Melendez T., Patel H.B., Perretti M. Role of melanocortin receptors in the regulation of gouty inflammation. Curr Rheumatol Rep 2011, 13:138-145.
16. Manna S.K., Aggarwal B.B. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol 1998, 161:2873-2880.
17. Lam C.W., Perretti M., Getting S.J. Melanocortin receptor signaling in RAW264.7 macrophage cell line. Peptides 2006, 27:404-412.
18. Kalden D.H., Scholzen T., Brzoska T., Luger T.A. Mechanisms of the antiinflammatory effects of alpha-MSH. Role of transcription factor NF-kappa B and adhesion molecule expression. Ann N Y Acad Sci 1999, 885:254-261.
19. Scholzen T.E., Sunderkotter C., Kalden D.H., Brzoska T., Fastrich M., Fisbeck T., et al. Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology 2003, 144:360-370.
20. Getting S.J., Gibbs L., Clark A.J., Flower R.J., Perretti M. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J Immunol 1999, 162:7446-7453.
21. Getting S.J., Lam C.W., Chen A.S., Grieco P., Perretti M. Melanocortin 3 receptors control crystal-induced inflammation. FASEB J 2006, 20:2234-2241.
22. Getting S.J., Christian H.C., Lam C.W., Gavins F.N., Flower R.J., Schioth H.B., et al. Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides: studies in the recessive yellow (e/e) mouse suggest an important role for melanocortin 3 receptor. J Immunol 2003, 170:3323-3330.
23. Capsoni F., Ongari A.M., Reali E., Catania A. Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Arthritis Res Ther 2009, 11:R151.
24. Ponticelli C., Passerini P., Salvadori M., Manno C., Viola B.F., Pasquali S., et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006, 47:233-240.
25. Brunson K.L., Avishai-Eliner S., Baram T.Z. ACTH treatment of infantile spasms: mechanisms of its effects in modulation of neuronal excitability. Int Rev Neurobiol 2002, 49:185-197.
26. Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
27. Jordan K.M., Cameron J.S., Snaith M., Zhang W., Doherty M., Seckl J., et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007, 46:1372-1374.
28. Khanna D., Khanna P.P., Fitzgerald J.D., Singh M.K., Bae S., Neogi T., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012, 64:1447-1461.